Literature DB >> 6718116

Cerebral blood flow in sickle cell cerebrovascular disease.

P R Huttenlocher, J W Moohr, L Johns, F D Brown.   

Abstract

Cerebral blood flow (CBF) has been studied by the xenon-133 (133Xe) inhalation method in 16 children with suspected sickle cell cerebrovascular disease. Abnormalities consisting of decreases in total, hemispheral, or regional CBF were found in 17 of 26 studies. Eleven studies performed immediately after stroke, transient ischemic attack, or depression of state of alertness showed abnormalities. In addition to confirming regional cerebrovascular insufficiency in children with stroke due to major cerebral artery occlusion, the method detected diffuse decrease in CBF in children with stupor, coma, and seizures who had normal angiographic findings. In contrast, six of seven studies obtained after exchange transfusion or during maintenance on hypertransfusion therapy showed normal findings. The difference between results in patients with acute neurologic disturbances and those receiving transfusion therapy was statistically significant (P less than .005). The data indicate that the 133Xe method reliably demonstrates cerebrovascular impairment in sickle cell disease. They also suggest that CBF changes in patients with sickle cell disease can be reversed by exchange transfusion and by hypertransfusion therapy. The 133Xe CBF method may be useful for following up children with sickle cell disease who are at high risk for recurrent stroke.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6718116

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  13 in total

Review 1.  The epidemiology, evaluation and treatment of stroke in adults with sickle cell disease.

Authors:  John J Strouse; Sophie Lanzkron; Victor Urrutia
Journal:  Expert Rev Hematol       Date:  2011-12       Impact factor: 2.929

2.  Cerebral blood flow mapping using stable xenon-enhanced CT in sickle cell cerebrovascular disease.

Authors:  Y Numaguchi; J S Haller; J R Humbert; A E Robinson; W W Lindstrom; L M Gruenauer; J E Carey
Journal:  Neuroradiology       Date:  1990       Impact factor: 2.804

Review 3.  Stroke in children with sickle cell anaemia: aetiology and treatment.

Authors:  C H Pegelow
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 4.  Neuropsychological aspects of pediatric sickle cell disease.

Authors:  M C Kral; R T Brown; G W Hynd
Journal:  Neuropsychol Rev       Date:  2001-12       Impact factor: 7.444

Review 5.  Hypoxic adaptation during development: relation to pattern of neurological presentation and cognitive disability.

Authors:  Fenella J Kirkham; Avijit K Datta
Journal:  Dev Sci       Date:  2006-07

Review 6.  Screening children for sickle cell vasculopathy: guidelines for transcranial Doppler evaluation.

Authors:  Dorothy Bulas
Journal:  Pediatr Radiol       Date:  2005-02-10

7.  Lower Transcranial Doppler Flow Velocities in Sickle Cell Anemia Patients on Hydroxyurea: Myth or Fact.

Authors:  Sawsan M Moeen; Ahmad F Thabet; Hosam A Hasan; Medhat A Saleh
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-08       Impact factor: 0.900

8.  Stroke in Children with Sickle Cell Disease.

Authors:  Fenella J. Kirkham; Michael R. DeBaun
Journal:  Curr Treat Options Neurol       Date:  2004-09       Impact factor: 3.598

9.  Cerebrovascular accidents in sickle cell disease. Risk factors and blood transfusion influence. French Study Group on Sickle Cell Disease.

Authors:  M de Montalembert; P Beauvais; D Bachir; F Galacteros; R Girot
Journal:  Eur J Pediatr       Date:  1993-03       Impact factor: 3.183

10.  Magnetic resonance imaging/angiography and transcranial Doppler velocities in sickle cell anemia: results from the SWiTCH trial.

Authors:  Kathleen J Helton; Robert J Adams; Karen L Kesler; Alex Lockhart; Banu Aygun; Catherine Driscoll; Matthew M Heeney; Sherron M Jackson; Lakshmanan Krishnamurti; Scott T Miller; Sharada A Sarnaik; William H Schultz; Russell E Ware
Journal:  Blood       Date:  2014-06-09       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.